This potential disease mechanism is supported by a previous single-arm, open-label trial in PD patients, targeting the same pathway by a combined treatment with inosine and an inhibitor of the enzyme XDH to block the conversion of hypoxanthine to xanthine75. The gene discussed is XDH; the disease is Parkinson disease.